These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32853682)

  • 1. Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT
    Kim M; Truss M; Pagare PP; Essandoh MA; Zhang Y; Williams DA
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127511. PubMed ID: 32853682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Characterization of 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC) and Its Analogues as Non-nitrogenous 5-HT2B Ligands.
    Williams DA; Zaidi SA; Zhang Y
    J Nat Prod; 2015 Aug; 78(8):1859-67. PubMed ID: 26270954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC): a novel non-nitrogenous ligand for 5-HT2B receptor.
    Williams DA; Zaidi SA; Zhang Y
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1489-92. PubMed ID: 24582985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.
    Kapadia N; Ahmed S; Harding WW
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3216-3219. PubMed ID: 27261181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.
    Moritomo A; Yamada H; Watanabe T; Itahana H; Akuzawa S; Okada M; Ohta M
    Bioorg Med Chem; 2013 Dec; 21(24):7841-52. PubMed ID: 24189186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BF-1--a novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs.
    Schmitz B; Ullmer C; Segelcke D; Gwarek M; Zhu XR; Lübbert H
    Eur J Pharmacol; 2015 Mar; 751():73-80. PubMed ID: 25666387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
    Brea J; Rodrigo J; Carrieri A; Sanz F; Cadavid MI; Enguix MJ; Villazón M; Mengod G; Caro Y; Masaguer CF; Raviña E; Centeno NB; Carotti A; Loza MI
    J Med Chem; 2002 Jan; 45(1):54-71. PubMed ID: 11754579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy.
    Cavero I; Guillon JM
    J Pharmacol Toxicol Methods; 2014; 69(2):150-61. PubMed ID: 24361689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.
    Moritomo A; Yamada H; Watanabe T; Itahana H; Koga Y; Akuzawa S; Okada M
    Bioorg Med Chem; 2014 Aug; 22(15):4323-37. PubMed ID: 24916029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.
    Wainscott DB; Sasso DA; Kursar JD; Baez M; Lucaites VL; Nelson DL
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):17-24. PubMed ID: 9459568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel A3 adenosine receptor ligands based on chromone scaffold.
    Gaspar A; Reis J; Kachler S; Paoletta S; Uriarte E; Klotz KN; Moro S; Borges F
    Biochem Pharmacol; 2012 Jul; 84(1):21-9. PubMed ID: 22433284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In search for new chemical entities as adenosine receptor ligands: development of agents based on benzo-γ-pyrone skeleton.
    Gaspar A; Reis J; Matos MJ; Uriarte E; Borges F
    Eur J Med Chem; 2012 Aug; 54():914-8. PubMed ID: 22703703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure activity relationships of 5-HT
    Tosh DK; Calkins MM; Ivancich MS; Bock HA; Campbell RG; Lewicki SA; Chen E; Gao ZG; McCorvy JD; Jacobson KA
    Eur J Med Chem; 2023 Nov; 259():115691. PubMed ID: 37562117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.
    Setola V; Dukat M; Glennon RA; Roth BL
    Mol Pharmacol; 2005 Jul; 68(1):20-33. PubMed ID: 15831837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
    Kekewska A; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and antiviral activity of 2-(3-amino-4-piperazinylphenyl)chromone derivatives.
    Kim MK; Yoon H; Barnard DL; Chong Y
    Chem Pharm Bull (Tokyo); 2013; 61(4):486-8. PubMed ID: 23546009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.
    Zhou Y; Ma J; Lin X; Huang XP; Wu K; Huang N
    J Med Chem; 2016 Jan; 59(2):707-20. PubMed ID: 26700945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging opportunities and concerns for drug discovery at serotonin 5-HT2B receptors.
    Brea J; Castro-Palomino J; Yeste S; Cubero E; Párraga A; Domínguez E; Loza MI
    Curr Top Med Chem; 2010; 10(5):493-503. PubMed ID: 20166944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
    Winter E; Lecerf-Schmidt F; Gozzi G; Peres B; Lightbody M; Gauthier C; Ozvegy-Laczka C; Szakacs G; Sarkadi B; Creczynski-Pasa TB; Boumendjel A; Di Pietro A
    J Med Chem; 2013 Dec; 56(24):9849-60. PubMed ID: 24304387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.